OTC Drugs

Analysts hold back on predicting new heights for B+L until full split from parent firm. It reported Q4 revenue up 9% to $1.28bn and full-year revenue up 16% to $4.79bn.

As many as 700 employees reportedly dismissed from posts starting on 14 February as the culling of the federal workforce by the Trump administration’s Department of Government Efficiency reaches FDA.

President Trump's Executive Order creating the commission names mental health and weight-loss drugs as treatments of concern. But it does not mention vaccines, which Kennedy has criticized.

Trade groups say they welcome working with Robert F. Kennedy Jr. on expanding and improving consumer access to OTC drugs and dietary supplements. White House “Department of Government Efficiency Workforce Optimization Initiative” limits filling federal agency vacancies.

A federal judge granted Doctors for America’s motion for a temporary restraining order directing the FDA and CDC to restore information removed from the agencies’ websites to comply with a presidential executive order targeting “gender ideology extremism.”

A federal judge granted Doctors for America’s motion for a temporary restraining order directing the FDA and CDC to restore information removed from the agencies’ websites to comply with a presidential executive order targeting “gender ideology extremism.”

In recent US consumer health space rebranding, VEGA pays homage to celestial origins; AN Performance formulations launched with Chiquita co-branding; Crown simplifies Blue Lizard Australian Sunscreen portfolio with products tailored to life stages; and AMMD packaging shows a modern and elevated look.

PCH announces 2.7 % reported growth to $290.3m in revenues for its latest quarter. Fleet line extensions don’t the brand against fiber product lines such as Metamucil and Benefiber. Licenses all markets for Hydralyte outside US. Two more Clear Eyes suppliers to be added as current pair repair their processes.

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

The Trump transition so far has all the hallmarks of the tech industry’s favorite management slogan, but that might not work well for biopharma companies if the FDA is one of the agencies that gets broken.